Abstracts tagged "Animal Model"

Abstract Number: 1753 • ACR Convergence 2025
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Christopher Ritchlin¹, Javier Rangel-Moreno², Angel Rangel-Garcia³, Marissa Krantz⁴, Madison Brien², Thiloginy Sathilaseenlan², Jeffrey Fox⁵, Ronald Wood² and Maria de la Luz Garcia-Hernandez³, ¹University of Rochester Medical Center, Canandaigua, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, West Henrietta, NY, ⁴University of Rochester, Bethesda, MD, ⁵University od Rochester, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic…
Abstract Number: 0949 • ACR Convergence 2025
The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis
Mehrnaz Gharaee-Kermani¹, Poulami Dey², Vincent van Drongelen¹, Joanna Rew¹, Rachael Bogle³, Marisa Hildebrandt¹, Benjamin Klein¹, Rezvan Moallemian¹, Monique E Verhaegen¹, Andrzej A Dlugosz⁴, Lam Tsoi¹, J. Michelle Kahlenberg¹, Johann Gudjonsson¹ and Allison C Billi¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Holland, OH, ⁴University of Michigan, Ann Arbor
Background/Purpose: Autoimmune disease is far more common in women than men. We have determined that the skin of healthy women is primed for autoimmunity due…
Abstract Number: 0080 • ACR Convergence 2025
The Role of DICAM in Modulating Macrophage Differentiation and Inflammatory Responses via αvβ3 Integrin Signaling in Rheumatoid Arthritis
Hanna Lee¹, Youn-Kwan Jung², Sang-il Lee³, Yun-Hong Cheon⁴ and Hyunjin Lim⁴, ¹Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Hospital, Changwon, Changwon-si, Kyongsang-namdo, Republic of Korea, ²Institute of Medical Science, Gyeongsang National University, Jinju, Jinju, Kyongsang-namdo, Republic of Korea, ³Department of Internal Medicine and Institute of Medical Science, College of Medicine, Gyeongsang National University and Hospital, Jinju, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Jinju, Kyongsang-namdo, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent joint inflammation, cartilage destruction, and bone erosion. Among the various immune cells involved…
Abstract Number: 1735 • ACR Convergence 2025
Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation
Elise Herardot¹, Nadine Soliman¹, Audrey Pigenet¹, Ilana Slotine¹, Anni Herranan², Samia Bahieddine¹, Jean-Baptiste Fini², Olivier Tabary¹, Adeline Cambon³, Xavier HOUARD⁴, Francis BERENBAUM⁵, SELLAM JEREMIE⁶ and Alice Courties⁷, ¹Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, Paris, France, ²UMR ⁷²²¹, Phyma, CNRS–Muséum National d’Histoire Naturelle, Sorbonne Université, ⁷⁵⁰⁰⁵ Paris, France, Paris, France, ³Department of Orthopedic, Trauma and Hand Surgery, Hôpital Saint-Antoine, Sorbonne University, ¹⁸⁴ Rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France, ⁴Centre de Recherche Saint-Antoine, UMR_S⁹³⁸ INSERM /Sorbonne Université, Paris, France, PARIS, France, ⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ⁶Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France, ⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹², Paris, France / Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France
Background/Purpose: Osteoarthritis (OA) affects over 590 million individuals globally. Epidemiological data suggest that exposure to environmental pollutants, particularly endocrine-disrupting chemicals (EDCs) such as phthalates, PFAS,…
Abstract Number: 0947 • ACR Convergence 2025
Mechanisms of anti-NMDAR antibody-mediated neuronal pathology and mitigation by angiotensin II signaling inhibition
Kaitlin Carroll¹, Mark Mizrachi¹, Sean Simmons², Bahtiyar Toz¹, Czeslawa Kowal³, Nazila Tehrani¹, Aida Zarfeshani¹, Nina Kello¹, Lara El Khoury⁴, Jeffrey Wingard¹, Rachel Weissman-Tsukamoto³, Joshua Levin², Bruce Volpe³ and Betty Diamond⁵, ¹Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, ²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, ³Feinstein Institute of Molecular Medicine, Manhasset, NY, ⁴Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁵The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment is a frequent manifestation of neuropsychiatric systemic lupus erythematosus, present in up to 80% of patients and leading to a diminished quality…
Abstract Number: 0064 • ACR Convergence 2025
Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
Tailin He and Yifang Mei, Shenzhen Third People's Hospital, Shenzhen, China (People's Republic)
Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…
Abstract Number: 1736 • ACR Convergence 2025
Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.
Kevin Burt¹, Sanique South², Natalie Adamczyk³, Shingo Ishihara³, Vu Nguyen⁴, Robert Mauck⁴, Anne-Marie Malfait⁵, Timothy Griffin⁶, Rachel Miller⁷ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Oregon, Eugene, ³Rush University, Chicago, ⁴University of Pennsylvania, Philadelphia, ⁵Rush University, Oak Park, IL, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷Rush University Medical Center, Chicago, IL
Background/Purpose: Soluble CD14, a co-receptor of inflammatory toll-like receptor signaling that is produced primarily by monocytes/macrophages, is present in synovial fluid in patients with OA…
Abstract Number: 0946 • ACR Convergence 2025
A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice
Juan Liang¹ and Ting Wang², ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic)
Background/Purpose: CD20, a well characterized B-cell surface marker involved in B-cell activation and differentiation, plays a critical role in the pathogenesis of B-cell mediated diseases…
Abstract Number: 0065 • ACR Convergence 2025
Expression and Co-Localization of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues Precedes the Development of Cardiac Fibrosis in Collagen-Induced Arthritis
Wenxian Zhou¹, Hannah Johnson², Michael Duryee², Ali Namvaran³, Julian Garcia², Carlos Hunter², Tate Johnson², Daniel Anderson⁴, Kishore Bidasee², Geoffrey Thiele² and Ted Mikuls², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, ^40587964, Durham, NC
Background/Purpose: Patients with rheumatoid arthritis (RA) experience increased morbidity and mortality due to heart failure with preserved ejection fraction (HFpEF), a condition characterized by diastolic…
Abstract Number: 1734 • ACR Convergence 2025
Intra‑articular Liraglutide Halts Osteoarthritis Progression, Surpassing Dexamethasone in Synovial and Cartilage Protection
Coralie Meurot¹, Celine Martin¹, Margot Vieubled², Indira Toillon³, Claire Deldycke¹, Valentine Cheron¹, Soline Trombetta¹, William Sibran¹, Revital Rattenbach¹ and Francis BERENBAUM⁴, ¹⁴P Pharma, Lille, France, ²⁴P Pharma, Lille, ³Sorbonne University, Paris, France, ⁴Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France
Background/Purpose: Osteoarthritis (OA) is an age-related joint disease that cause chronic pain and reduced mobility. Current treatments mainly relieve pain and inflammation, often with corticosteroid…
Abstract Number: 0942 • ACR Convergence 2025
Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
Jennifer Nicholson¹, Maria Ossa-Echeverri¹, Arpitha Haranahalli Shivarudrappa¹, Mark Lusco¹, Maria de la Luz Garcia-Hernandez², John Looney¹, Jennifer Anolik³ and Javier Rangel-Moreno¹, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Though immune targeted therapies have improved outcomes in lupus nephritis, a significant number of patients experience renal damage and even progression to end stage…
Abstract Number: 0058 • ACR Convergence 2025
Training for increased inflammatory arthritis in mice is not modulated by type 1 interferon
Richard Bell¹, Mary Huang¹, Claire Weigert², Ruoxi Yuan², Toolika Singh², Seda Seren² and Lionel Ivashkiv¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York
Background/Purpose: Disease flares, or episodic escalating inflammation, is a hallmark of autoimmune diseases, like Rheumatoid Arthritis (RA). They are particularly hard to predict and treat…
Abstract Number: 1206 • ACR Convergence 2025
Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Juliane Bremer¹, Judith Nagel², Jana Zschüntzsch³, Kamil K Zajt¹, Tayfun Palaz¹, Thomas Blank⁴, Aylin Ikis¹, Laura A Fischer³, Anna SM Sensmeyer³, Lara Wiechers³, Josef J Reichelt³, Kai P Hofmann⁵, Monika J Wolf⁶, Corinna Leuchtenberger⁷, Priyanka Tripathi¹, Claudia Einer⁸, Hans Zischka², Ulrike Rothermel⁷, Anna L Eck⁷, Regina Reimann⁹, Veronika Kana⁶, Elisabeth Rushing⁶, Adriano Aguzzi⁶, Marco Prinz⁴, David Liebetanz³, Francesca Odoardi³, Chao-Chung Kuo¹, Joachim Weis¹, Florian Kraft¹, Jens Schmidt¹⁰ and Mathias Heikenwälder⁷, ¹University Hospital RWTH Aachen, Aachen, Germany, ²Technical University of Munich, München, Germany, ³University Medical Center Göttingen, Göttingen, Germany, ⁴University of Freiburg, Freiburg, Germany, ⁵DKFZ Heidelberg, Göttingen, Germany, ⁶University Hospital Zürich, Zürich, Switzerland, ⁷DKFZ Heidelberg, Heidelberg, Germany, ⁸Helmholtz Munich, München, Germany, ⁹University Hospital Zürich, Zürich, Germany, ¹⁰Immanuel University Hospital Rüdersdorf, Brandenburg Medical School, Rüdersdorf bei Berlin, Germany
Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disorder characterized by inflammation and degeneration with altered proteostasis. To better understand the interrelationship between these…
Abstract Number: 0941 • ACR Convergence 2025
In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Juliet Crabtree, Thomas Lee, David Soto, Prapti Vyas, Akinola Emmanuel, Matthew Theisen, Karolina Kosakowska, Maja Sedic, Rajat Das, Muthusamy Jayaraman, Megan Hoban, Joe Bolen and Isin Dalkilic-Liddle, Orna Therapeutics, watertown, MA
Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and…
Abstract Number: 0053 • ACR Convergence 2025
The Integrin Inhibitor Cilengitide Targets CCN1-Mediated Angiogenesis and Reduces Disease Severity in a Preclinical Rheumatoid Arthritis Model
Jérôme Avouac¹, manon lesturgie², Virginie Gonzalez³, Sujeeba Arulananthan², Anne Cauvet³, Francoise Tilotta⁴ and Yannick Allanore⁵, ¹Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ²INSERM U¹⁰¹⁶, Paris, France, ³INSERMU¹⁰¹⁶, Paris, France, ⁴Université Paris Cité, Montrouge, France, ⁵Université Paris Cité, Paris, France
Background/Purpose: CCN1, a matricellular protein with angiogenic and immunomodulatory properties, is overexpressed in endothelial and synovial tissues of rheumatoid arthritis (RA) patients. Previous findings demonstrated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].